Coagulation factor ix (recombinant), albumin fusion protein - Biologic Drug Details

Summary for coagulation factor ix (recombinant), albumin fusion protein

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for coagulation factor ix (recombinant), albumin fusion protein Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for coagulation factor ix (recombinant), albumin fusion protein Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Csl Behring Lengnau Ag	IDELVION	coagulation factor ix (recombinant), albumin fusion protein	For Injection	125582		2027-12-17	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for coagulation factor ix (recombinant), albumin fusion protein Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Csl Behring Lengnau Ag	IDELVION	coagulation factor ix (recombinant), albumin fusion protein	For Injection	125582		2027-07-11	Patent claims search

International Patents for coagulation factor ix (recombinant), albumin fusion protein

Country	Patent Number	Estimated Expiration
South Korea	20140101877
Japan	5800458
European Patent Office	3564267
European Patent Office	1867660

Supplementary Protection Certificates for coagulation factor ix (recombinant), albumin fusion protein

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
16C1005	France		PRODUCT NAME: ALBUTREPENONACOG ALFA; REGISTRATION NO/DATE: EU/1/16/1095 20160513
CR 2016 00039	Denmark		PRODUCT NAME: REKOMBINANT FUSIONSPROTEIN, HVOR KOAGULATIONSFAKTOR IX ER LINKET TIL ALBUMIN, SVARENDE TIL ALBUTREPENONACOG ALFA; REG. NO/DATE: EU/1/16/1095 20160513
CA 2016 00039	Denmark		PRODUCT NAME: REKOMBINANT FUSIONSPROTEIN, HVOR KOAGULATIONSFAKTOR IX ER LINKET TIL ALBUMIN; REG. NO/DATE: EU/1/16/1095 20160513
300828	Netherlands		PRODUCT NAME: ALBUTREPENONACOG ALFA; REGISTRATION NO/DATE: EU/1/16/1095 20160513

Coagulation factor ix (recombinant), albumin fusion protein Market Analysis and Financial Projection

Last updated: February 15, 2026

Market Dynamics and Financial Trajectory for Recombinant Coagulation Factor IX Albumin Fusion Protein

Market Overview

Recombinant coagulation factor IX (rFIX) fused with albumin is a targeted therapy for hemophilia B. Enhancements in pharmacokinetics and extended half-life over traditional plasma-derived or recombinant FIX products have driven R&D activity, regulatory approvals, and commercial interest. The fusion extends dosing intervals from 3–4 days to up to 14 days or longer.

Competitive Landscape

Major players include:

• CSL Behring: Introduced Idelvion (rFIX-Fc fusion), approved in 2016, with a focus on extended dosing.
• Pfizer/Changzhou: Developing rFIX-Fc biosimilars.
• Shire (now part of Takeda): Offers Rebinyn (non-fusion rFIX), but has not launched fusion proteins.

Emerging firms exploring novel albumin-fusion strategies aim to optimize half-life and immunogenicity profiles.

Regulatory Milestones

• Idelvion (CSL Behring): Approved by FDA (2016), EMA (2017). Approved in multiple regions.
• Regulatory pathways favor orphan drug incentives, orphan designation benefits, and potential for priority review.

Financial Trajectory

R&D Investment

Development stages estimate a minimum of $150–$250 million per molecule, including preclinical, clinical, and regulatory costs. Fusion proteins demand complex manufacturing, boosting costs relative to standard rFIX.

Revenue Projections

• Market Size: Global hemophilia B market was valued at approximately $1.2 billion in 2022.
• Adoption: Fusion proteins capturing 30–50% of the hemophilia B segment over 5–7 years.

Based on current penetration rates, revenue projections depend on:

• Pricing: Fusion products sell at a premium; estimates range $1.5 million–$2 million per patient annually.
• Patient Population: Estimated at 4,000–5,000 globally with moderate growth.

Assuming a 40% market share by 2028:	Year	Estimated Revenue (USD billions)	Notes
2023	0.1	Limited adoption, early market
2025	0.5	Uptake accelerates, broader approvals
2028	1.0 – 1.2	Market penetration stabilizes

Market Drivers

• Longer dosing intervals improve patient adherence.
• Reduced infusion frequency lowers treatment burden.
• Favorable regulatory landscape supports accelerated approvals.

Market Challenges

• High manufacturing costs limit pricing strategies.
• Competition from gene therapy approaches may impact long-term outlook.
• Variability in healthcare reimbursement policies across regions.

Future Outlook and Investment Considerations

Innovation in fusion protein design aims to improve immunogenicity and pharmacodynamics. Strategic partnerships, licensing agreements, and patent protections influence market entry and pricing.

The long-term financial trajectory hinges on:

• Regulatory acceptance of novel formulations.
• Clinical trial outcomes demonstrating safety and efficacy.
• Market acceptance driven by economic and patient preference factors.

Patent expiry for first-generation products, expected around 2030, opens opportunities for biosimilars but also intensifies competition.

Key Takeaways

• The recombinant albumin-FIX fusion protein aligns with improving hemophilia B management.
• Major approvals occurred since 2016, with projections forecasting significant revenue growth by 2028.
• High manufacturing costs and evolving competition influence profitability.
• The market is characterized by regulatory incentives and emerging biosimilars.

FAQs

1. How does albumin fusion extend the half-life of coagulation factor IX?
Albumin fusion leverages albumin's natural long half-life (about 19 days) to stabilize the fused FIX molecule, reducing renal clearance and degradation, leading to less frequent dosing.

2. What are the primary regulatory hurdles for fusion proteins in hemophilia B?
Manufacturing complexity, demonstrating bioequivalence with existing therapies, proving long-term safety, and addressing immunogenicity are key hurdles.

3. How does market competition impact the profitability of recombinant fusion FIX products?
Competition from biosimilars and gene therapies pressures pricing and market share, impacting revenue streams and requiring differentiation through improved efficacy or convenience.

4. What is the role of gene therapy in the future of hemophilia B treatment?
Gene therapy can potentially provide a one-time curative approach, impacting long-term market demand for recombinant products.

5. Which regions are most promising for commercialization?
North America and Europe lead due to established hemophilia treatment infrastructure and favorable regulatory environments. Emerging markets show growth potential with expanding healthcare access.

References

1. Hemophilia Market Size & Trends, Global Data, 2022.
2. FDA Approvals and Regulatory Pathways, US FDA, 2016–2022.
3. CSL Behring Product Profiles, Corporate Reports, 2022.
4. Biosimilar and Biologic Market Dynamics, IQVIA, 2021.
5. Hemophilia B Therapeutics Market Report, EvaluatePharma, 2022.